GH Research (GHRS) Short Interest Ratio & Short Volume

Short interest is the volume of GH Research shares that have been sold short but have not yet been covered or closed out. As of November 30th, investors have sold 1,980,000 shares of GHRS short. 6.50% of GH Research's shares are currently sold short. Learn More on GH Research's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GHRS shares currently have a short interest ratio of 33.0. Learn More on GH Research's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of GH Research: PEAK6 Investments LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.50% of GH Research's floating shares are currently sold short.

GH Research currently has issued a total of 52,028,000 shares. Some of GH Research's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. GH Research currently has a public float of 30,440,000 shares.

6.50% of GH Research's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to GH Research: NewAmsterdam Pharma (6.04%), Evotec SE (0.14%), Arcus Biosciences, Inc. (16.69%), Immunocore Holdings plc (14.78%), Kiniksa Pharmaceuticals, Ltd. (5.57%), Intellia Therapeutics, Inc. (18.57%), Ocular Therapeutix, Inc. (6.78%), Arcutis Biotherapeutics, Inc. (20.10%), Travere Therapeutics, Inc. (9.70%), Nurix Therapeutics, Inc. (13.20%),

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks.

Short selling GHRS is an investing strategy that aims to generate trading profit from GH Research as its price is falling. GHRS shares are trading up $0.26 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for GH Research occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GHRS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GHRS, twice per month. The most recent reporting period available is November, 30 2024.